The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the ...

The fluorescent labeling compound—dubbed "Sialyl Lewis Yellow"—was developed by an international team led from the Pohang University of Science and Technology in South Korea. It works by binding to ...

A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center may help explain why certain liver ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today ...

"PanTher Therapeutics launches second trial for chemotherapy patch" was originally created and published by Clinical Trials ...

Earlier diagnoses and advancements in treatment options are providing hope for patients with endometrial cancer like Yaca.

Paclitaxel (PTX) has emerged as one of the first-line drug candidates in cancer therapy due to its potency and profound anticancer potential. Derived from a rich natural source, it stands out as a ...

The first trial of adjuvant platinum-based chemotherapy plus paclitaxel in patients with high-risk penile cancer provided some insights.

CHICAGO -- A neoadjuvant chemotherapy regimen of cisplatin (Platinol), nab-paclitaxel (Abraxane), capecitabine (Xeloda), and gemcitabine (PAXG) topped a standard option in a randomized trial of ...

The trial showed numerically higher median PFS and OS in the paclitaxel group compared to the 5-FU group in high-risk penile cancer patients. The 5-FU arm experienced higher incidences of grade 3-4 ...

A randomized phase 2 study of a GSK-3ß inhibitor plus gemcitabine/nab-paclitaxel showed survival benefit in patients with untreated metastatic pancreatic ductal ...

Breast cancer specialists who were not associated with the study applauded the results, saying blood tests could transform the way they monitor patients.